Trial data comparison: difference between revisions
Diff·revision 32 → 33·14:59, 27 May 2025
Difference between revision 32 and revision 33 of Trial data comparison. 4 lines changed; the page grew by 488 bytes.
| Revision 32 — 01:09, 22 May 2025 CPeptidePaddy (talk) rv addition of price information per PP:VN 4,437 bytes +82 | Revision 33 — 14:59, 27 May 2025 SemaxSevi (talk) add PMID 4,925 bytes +488 | ||
|---|---|---|---|
| 41 | | Not stated | — | Unusable for comparison | | 41 | | Not stated | — | Unusable for comparison | |
| 42 | 42 | ||
| + | 43 | The SURMOUNT programme's publications state their estimand explicitly, which is why the tirzepatide rows in the table above can be compared with each other with more confidence than the cross-programme rows can.{{r|surmount1}} | |
| + | 44 | ||
| 43 | == References == | 45 | == References == |
| 44 | {{reflist}} | 46 | {{reflist}} |
| ⋮ | ⋮ | ||
| 46 | <ref name="step1">Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> | 48 | <ref name="step1">Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). DOI:10.1056/NEJMoa2032183. PMID 33567185.</ref> |
| 47 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 49 | <ref name="surpass2">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| + | 50 | <ref name="surmount1">Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." ''New England Journal of Medicine'' 387(3):205–216 (2022). DOI:10.1056/NEJMoa2206038. PMID 35658024.</ref> | |
| 48 | 51 | ||
| 49 | == See also == | 52 | == See also == |
| ⋮ | ⋮ | ||
| 53 | * [[SELECT trial]] | 56 | * [[SELECT trial]] |
| 54 | * [[Intention-to-treat analysis]] | 57 | * [[Intention-to-treat analysis]] |
| + | 58 | * [[Placebo-adjusted effect]] | |
| 55 | 59 | ||
| 56 | {{DEFAULTSORT:Trial data comparison}} | 60 | {{DEFAULTSORT:Trial data comparison}} |